GNLX 2.75 Genelux Corporation
| Range: | 1.6-20.25 | Vol Avg: | 147560 | Last Div: | 0 | Changes: | -0.06 |
| Beta: | -3.17 | Cap: | 0.09B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jan 26 2023 | Empoloyees: | 24 | ||
| CUSIP: | CIK: | 0001231457 | ISIN: | US36870H1032 | Country: | US | |
| CEO: | Mr. Thomas Zindrick J.D. | Website: | https://www.genelux.com | ||||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Stock Details
Positive 1.00
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: G...
globenewswire.com·Wed Oct 09 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow